This trial is active, not recruiting.

Conditions coronary heart disease, diabetes, vascular lesions, chronic total occlusion of coronary artery, restenosis
Treatment taxus™ element long stent
Sponsor Centre Chirurgical Marie Lannelongue
Collaborator Cochin Hospital
Start date October 2012
End date April 2017
Trial size 300 participants
Trial identifier NCT01861860, P12-37811002 / 2012-A00696-37


Rationale IVUS has shown to be efficient for bare metal stent deployment, but has not been specifically studied for Drug Eluting Stents. The angiographically versus IVUS optimization (AVIO) study was performed with (medical device's type )Promus stent, results are promising, but the study was not designed for clinical endpoint.

There is no consensus on IVUS criteria for stent deployment. The MUSIC criteria were widely used in the early 2000, but have limitations for complex long lesions. The AVIO criteria were recently proposed for complex lesions, but these criteria also have some issues and the complexity make their routine use challenging.

We performed a pilot study for long complex lesion analysis using IVUS, in order to define easy to use criteria, applicable for complex lesions in drug eluting stents (DES) era. The new criteria (OPERA) are an adaptation of the MUSIC criteria.

OTELLO study is an ongoing trial sponsored by Boston Scientific Inc, to determine Major Adverse Cardiac Event with the new TAXUS Element stent. 500 patients will be enrolled in the study.

Main question Is IVUS using simplified new criteria beneficial for long (>28mm) TAXUS element stent deployment?

Study design This study will consist to prospectively include consecutive patients with>28mm taxus element stent using IVUS. OPERA Criteria for stent deployment will be the objectives to reach. OPERA is an adaptation of the MUSIC criteria for long complex lesion. The patients from the OTELLO study, with the same inclusion criteria, will composed the control group . Population will be matched using the propensity score.

20 to 30 French centers involved in OTELLO study will be contacted for participating in OPERA.


Long lesion percutaneous coronary intervention(PCI) have specific characteristics like Diffuse old atheroma Calcifications Discrepancies between prox and distal diameter Infiltration longer than the target lesion Bifurcations Inhomogeneous strength due to the balloon (Laplace law) Primary hypothesis Long Taxus element deployed using IVUS and OPERA criteria have better outcomes than without IVUS

Primary Objectives 38% MACE (SAT, target lesion revascularization (TLR), myocardial infarction (MI), Death) reduction using IVUS and OPERA criteria for Taxus element ≥ 28 mm implantation

Secondary endpoint

1. MACE determination for Taxus element ≥ 28 mm implantation with IVUS and OPERA criteria

2. Safety: procedural Stroke, Urgent cardiac surgery, procedural MI

3. Comparison of IVUS criteria: OPERA, MUSIC, AVIO

Secondary objectives Safety of OPERA criteria Feasibility of using OPERA criteria in non expert IVUS center MACE determination with a 4% margin error for Taxus element ≥ 28 mm implantation with IVUS and OPERA criteria

Methods Inclusion of consecutive patients using IVUS Taxus element ≥ 28 mm in a multicentric study propensity score matched analysis matched for comparison to OTELLO study. (Same inclusion criteria as OTELLO)

Statistical analysis Primary Endpoint: MACE expected in the OTELLO study=18% MACE expected in the OPERA study=11% Number of patient in the OTELLO study=500 Alpha=0.05,1- Beta=0.73 Number of patients analysable in the OPERA study needed =250 patients i.e 300 pts inclusions.

Secondary Endpoint 4% margin error with a MACE of 11% need also 250 pts

Type of study Biomedical research French study Centralized IVUS analysis 1, 6 and 12 months telephone contact

Safety and efficacy measures Efficacy: MACE (Cardiac Death, target vessel revascularization (TVR), Myocardial Infarction) at 12 months Safety: procedure related event: Urgent surgery, According to Good Clinical Practices serious adverse event (SAE) declared within 24 Hours

United States No locations recruiting
Other countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose diagnostic
TAXUS™ Element long stent
taxus™ element long stent
Segments are selected using bifurcation branch take-off. The reference is selected or estimated on both sides of the bifurcation and is applied to the concerned segment. The objective is to attain > 80% of the reference cross-sectional areas (CSA) per segment. The balloon diameter is adapted to the endoluminal diameter of the reference.

Primary Outcomes

The incidence of MACE composite criteria among patients who received a TAXUS long stent deployed using IVUS according to the OPERA criteria according to the LPPR during a 12 months period after inclusion in the trial.
time frame: 12 months period after inclusion in the trial

Secondary Outcomes

The incidence of the MACE composite criteria at 6 months, 12 months and 3 years.
time frame: 6 months, 12 months and 3 years
The incidence of individual components of the MACE composite criteria at 6 months, 12 months and 3 years.
time frame: 6 months, 12 months and 3 years
The occurrence of follow-on events over a period of 6 months, 12 months and 3 years.
time frame: 6 months, 12 months and 3 years
Stent thrombosis at 12 months
time frame: 12 months
Medico-economics data at 12 months including
time frame: At 12 months including

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Age > 18 years - Patients who have had a coronary angioplasty with implantation of a TAXUS™ Element™ stent of 28, 32 and 38 mm in length and up to 3 stents per patient in the case of acute occlusive dissection deployed using IVUS - Patients with indication of Taxus™ Element™ stent included in the List of Reimbursable Products and Supplies (LPPR): - diabetes, - small vessel (less than 3 mm in diameter), - long lesion(s) (more than 15 mm long), - chronic total occlusion > 1 month, - intra-stent restenosis with the exclusion drug eluting stent(s), restenosis of - people with a lesion that is accessible to IVUS after stenting - people who have provided consent for collection of medical data for this trial. Exclusion Criteria: -Those who refuse to consent to the collection and/or processing of data necessary to complete the trial and/or the centralized follow-up

Additional Information

Official title OPtimized Stenting Using IVUS in Long lEsion: Rationale for Simplified criteriA
Principal investigator PHILIPPE DELEUZE, MD
Trial information was received from ClinicalTrials.gov and was last updated in March 2016.
Information provided to ClinicalTrials.gov by Centre Chirurgical Marie Lannelongue.